while we have you, gilead is facing pressure to lower the cost of hepatitis c. is this another chapter here opening in this story? >> it certainly a new headline. yesterday it became public that the massachusetts attorney general had sent a letter to gilead asking -- raising the probability that pricing of hepatitis c drug could violate massachusetts law. this is something that surprised a lot of people. it's not totally clear how that would work. as you mention this has been something going on for years. i think we have a time line looking back how this pressure started to mount on gilead, first hepatitis c drug, this represents a breakthrough for patients and cures more than 90% of people and don't have to use horrible ingestions that made every sick. a couple of months later, waxman sent a letter to the company questioning the pricing of the drug, $84,000 for 12 weeks of treatment, $1,000 a day. and that letter really affected the stock and industry. the combo pill was approved and it eclipsed all systems billions of dollars in sales. december 2014, it's comp

you look at gilead, amgen and celgene.ilead trading 7 times earnings down from 40 times beginning of 2014. it came down because that's around the time the drug pricing pressure started to ratchet up. we talked about drug pricing when there were real companies like gilead. it started to come down. gilead is trading at this level because people don't know what is going to happen after they cure everybody of hepatitis-c. folks are asking who are they going to buy. they think it should be trading higher. >> how does amgen compare? >> a higher multiple trading 20 times earnings compared with gilead's seven times. sorry. trading 15 times down from a high of 20 times. all these biotechs are down right now. celgene is the same. people say these are really great looking stocks. they've got a lot of earnings visibility. if you look at the top six pi techs in the ibb, they are trading 18 times 2016 earnings compared to 14, 15 for the s&p 500. they've got earnings expectations for 11% this year. that's why analysts are arguing these b

>> gilead up almost three bucks today, it's too cheap to sell. bob? >> caller: hello, jim, i hope you're warm and safe in the blizzard. jim, i was able to get on your show six months ago and this is a fofoow-up question. a close friend is a leading oncologist in philadelphia and he told me to buy tg therapeutics. i did and heard michael weiss on your show and was blown away and i bought more. tg presented in december and their blood cancer data was outstanding. they also discuss their opportunity in auto immune disease for the first time and that's amazing. i plan to buy more and want to get your opinion. >> the fundamentals are divorced from what's happening in the stocks and weiss is good, we had him on the show. here's the problem, it's a speculative stock. if you look pat gilead and cell genehey are so people people say why do i need to go down to tg therapepeics but if you hold on to the speculative the stock and hit it out of the park, you'll make money. harvey in florida. >> caller: how are you doing? >> i'm doing all right, how about you, harv

they once made up a majority of gilead's sales but competition has been eating into revenue.hares of the company up more than 1% on the day in the 99.26. spirit airlines chief executive steps down and company shares step up. he had been in the job since 2006. he gets credit for keeping ticket prices low while boosting fees. shares rising almost 6% today to 41.50. >>> meantime, three major carriers increased air fares. delta raised fees by up to $4 one way. southwest and american increased ticket prices by $3. shares of delta fell slightly to 48.57, southwest rose. and american airlines finished done nearly 1%. >>> amazon says customers ordered more than 23 million items from sellers on cyber-monday. an increase from the previous year. the retailer delivered more than 1 billion items sold by third party vendors in 2015 through its fulfillment by amazon service. a third party sellers are able to store their products in amazon's warehouses which enables amazon to fulfill the recordses directly. shares of the company down to 6.33.79. >> amazon is teaming up with an automaker. tod

>> yeah, we own gilead still.e sold macy's earlier in the year when we saw that cheaper oil prices and gas prices weren't helping consumers. and unfortunately, we still own devon. we think it's probably oversold. >> you think it's oversold. all right. let's talk about the market in general. you just heard a forecast by a number of people that 2016 may be more of the same. do you agree with that? >> yeah-i think we're going to have some fits and starts in this market. if you look at next year's earnings, the s&p we think is going to earn about $125, which gets you to about 2,200 in the s&p, sue. 6%-ish return. 6% to 7% with dividends a little more than that. but it's going to be a dramamine kind of year. we're going to have a lot of volatility that's going to make people a little nauseous. >> but you contend that you can profit from volatility if your timing is right, correct? >> yeah, i think if you have cash on the sidelines right now you should be picking your points of where you want entry either into the marke

am gen at 16.5 and 17 times forward earnings and gilead. >> i go right to am gen.l gen, there is controversy. and this stock was down to 148. i was staring at it and thinking about it and never pulled the trigger and now kicking myself. finishing at 155. it sells off again. i think it was down to the 130s. that is a huge screaming buy at 16 times. >> i thought gilead, which is a name we talked about with gee. but in the depth of the worst of today, it kind of hung in there. it was down some of the -- of the etfs in general. it just seemed like, wow, they can't go down that much more even though some are big momentum names. i think it is over for now, in the biotech selloff. >>> still ahead, some of the biggest tech ipos in the last year are trading below the ipo price. will it mean less companies are willing to take the public plunge? we have the details next. much more "fast money" still ahead, so don't move. iall across the state belthe economy is growing,day. with creative new business incentives, and the lowest taxes in decades, attracting the talent and compan

in her letter to gilead, she urges them to enable disease eradication. we had the massachusetts attorney general on, and we asked her how the pricing strategy breaks the law. she didn't really give us a clear answer on that. it's a tough time for gilead right now. >> the letter accusing them of potentially breaking the law through pricing, comes over a year, since the drug was on the market. we're already talking about top comparisons. because we've gone through whole cycles with the hep-c drug on the market. >> it's been on the market since december of 2013. they talk about fairness, so we're curious to know how it breaks the law. >> meg, thank you. broader biotech getting hit hard today, hitting lows not seen since 2014. she's talking about amgen. and good numbers from biogen as well. >> it's hardly moving. >> although, you know, when you have sentiment like this, and for three or information years, a giant swing, the pendulum doesn't stop when it goes back to fair value, it keeps going. i think we have a ways to go before you see the bottom. >> huge e

. >> wise gilead?e bare case has been their engine, merck, not a surprise, approval the other day. they'll buy something, but tough waiting for it. >> time for a segment we call motif of the month. here ardeep walia with the big unveil of the latest and greatest motif and it is -- >> electronic trading. rocky start to the year. people want to play defensive, low beta, dividend plays. this is a way to play offense on volatility. volatility goes up, trading volume goes up, companies that again benefit in january, equities higher than any point in 2015, might be true of options too, might find out in the next few days. >> talking exchanges. >> exchanges, cbo, nasdaq, intercontinental exchange group, platform plays like virtue is in there, kcg is in there. market access holding up almost 50% for the year. and this motif is up 14.2% one year versus down 4.9% for the s&p. xlf as an index 7.1 over the same period. >> what do you think of these -- >> interesting, so it is like the extreme, like tail end, right

say, no, we think you will pay the price because we think you have to >> reporter: the drug matter gilead declined an interview but in an email defended the price of the treatment. arguing that the one time cost appeals in comparison to the life time cost of treating the disease. with drug costs already as much as 15% of state medicaid budgets, add more miracle drugs being invented, analysts say hepatitis c drugs could be the first test of how america's budget can be stretched and whose cure society is willing to pay for. this woman who has no history of iv drug use sees the repeated denials as proof insurers don't care if she lives or dies. >> i think that's what the insurance companies want you to do. they want you to get discouraged. >> reporter: she isn't about to give up. >> i'm worth having this drug. i'm worth it. >> reporter: even if it's a hundred thousand dollars. >> even if it's a hundred thousand dollars. my life is worth saving. >> reporter: she is right. sips we first told you her story, she appealed the fourth denial and has now finally been approved. weeks from now, she ho

and then let's put gilead in that mix. those are high cross stocks. they do better. i'm not as concerned or negative as most of the people although it did rally today. all right. sometimes the market wants to go lower. we have to accept that. when it gets this negative i am urging actually calm. i want you to consider even as the market goes lower picking a favorite stock that's now at your price. all right on "mad money" tonight i already examined the winners and losers in 2015. tonight i'm eyeing the nasdaq. could the crash in crude continue? mr. wonderful himself. kevin o'leary can brighten up a little bit of sunshine in the show. stick with cramer. >> you're out of your mind putting a $10 million value on this. >> don't miss a second of "mad money." have a question, tweet cramer. #"mad tweets." send jim an e-mail to madmoney@cnbc.com or give us a head to madmoney.cnbc.com. >> i am urging you to remember that stocks can go up too. it's in this difficult environment that you need to be more selective. all week we have been examining the biggest winners of 2015. fir

. >> same kind of pill and that's 30% lower than gilead.hey had a monopoly on a drug costing a lot of money and it wasabout a better price by 10,000. >> and there was a lot of focus on the drug and what it's costing and at the same time it cures the disease. it's 12 weeks. >> again, i'm using these as met forical. i thought master card reported a great quarter and the visa did. i mean, they're down. they're just doing fabulously. >> stocks will be down, we should get to amazon, which is down rather sharply. fourth quarter results were below wall street expectations and a 22% jump in revenue. so, top line was up 22%. and the company's earnings released, ceobezos said " that said, this was the best performer last year, it has suffered this year and again today in the stock market, despite that 22% top line greth and $100 billion revenue. >> the stock was up very big yesterday. look, i went over the quarter. these are conference kaulz, it's basically kind of a -- we're basically a team that works together. you listen to amazon calls, could you

sco is up in gilead is up by 1.5. it's interesting what a difference a day makes. stocks are going up. exxon mobil and chevron and 2%-percentr are up and financial winners were the third biggest loser yesterday. they are now the third biggest s&p winner with berkshire hathaway and bank of america up by about 2.5%. sectors are green across the board s&p 500 is just about at its session high. mark: investors are bailing from vix funds like never before with 500 billion dollars coming out of the one of the most popular exchange traded products. this move say about the direction volatility will go? let's bring in camilla rousseau. thanks for joining us. investors are withdrawing money from securities that profit from higher volatility even as the vix itself is set for his biggest monthly gain since august. what is going on? >> it seems strange but the two most popular etf's tracking the vix which shows volatility in the market are having outflows they are having 500 million which is a record for any month. that chartsllar one the same indexes having 300 million of outf

i don't know about gilead. it's been more pharma than biotech. pharma. people like pharma.ou got one candidate bernie sanders who i think says she's companies are really just a tech consumer, hillary attacking left and donald trump out there saying medicare should argue and be a bedating and trying to get lower prices. that is by far the furthest left of the positions. i don't know if the democratic -- shoot, he's republican. >> yes, he is. >> that oil trade we talked about this morning, best performing dow component. exxon and chevron are not far behind. >> royal dutch is down 25%. the capital budgets are down. i think that remember, when you see these kinds of runs in oil, it has been often refuted, russia is pumping more than anyone in the world right now. even more than the saudis. russia needs that capital. the saudi article saying they have about $1.50 cost. our average cost for much of these shales is $45. >> is that really their cost? >> yeah. >> i'm saying the saudis is that low? >> it's amazing. saudis are doing some fracking work. so let's not say saudis are goin

off on aares are boston globe report that the massachusetts attorney general says gilead may face legaln unless it lowers the pricing on its hepatitis b drugs. betty: thank you so much. abigail doolittle, live at the nasdaq. biotech drugs, fourth-quarter earnings missing estimates. revenue plunged in its alcon eye care unit. the company's new or drugs and pipeline. mark: here is what the chief executive told us on bloomberg about demand for its new drug. >> if you look at the innovation machine novartis is in the pharmaceutical division, we have generated a number of new medicines that are growing significantly. parte offsetting a large of that patent expiration. mark: bloomberg intelligence analysts santa rosa sam fazeli. does it fit into the novartis world? sam: great question. exact question was asked on the call by one of the analysts. the real answer is no. there is no obvious crossfield. apart.e farm this is a medical device business. they are saying they want to be businesses that are the leaders in those fields. anything in the health care world could fit that description for no

guys like gilead trading at 8.5, nine times. a lot of fund managers say these things.iated, well understood. a lot of this is priced in. >> even if the economy sputters here a little bit, i would imagine that health care, given our demographic, given where spending seems to be going, seems like a pretty great place to be putting your money. the valuation comes down. which side are you playing? >> i think all of those fundamentals are right in the longer term. with biogen, some stuff people are very focused on. i think if you look at names like gilead, or sell jean, which created 12% growth, you're going to be well positioned. il stuff, the china stuff certainly is not impacting whatever is going on on alzheimer's. >> yeah. well, that's a point. but also not helping out there in the space. thanks a lot for joining us. >> absolutely. >> mike there from rbc capital markets. we've got more breaking news on gopro. let's get back to josh lipton. >> well, kelly, so we had this news from gopro preannouncing q4 results that were a disappointment. i now have a letter from gopro'

we have a couple of names to the upside here, and i would say biotech, certainly gilead, valeant, eli liller is a bigger broader health care name and talk pharmaceuticals here, pfizer is pretty much flat. daal. that shares of mcdonald's, real green here, they touched a new lifetime high of $121.90 a share. shortly after today's open, they pulled back now, people are selling and trying to gain profits here, up about 1.25%. new record close, mcd must finish above $120.07, that's the number to watch. we're not there just yet. let's get on wall street. the snow definitely could not stop wall street today. markets are open. we've got a megamerger between tyco and johnson controls. volume currently running about 4% below average on the big board. but do we have at least the beginnings of a clear answer as to whether stocks are close to a bottom? get right to the floor show, traders at the new york stock exchange and cme group. so today we've got oil dropping about 6%, it wasn't the iranians but the iraqis to blame. blurting out today, we have record high production, yeah, that means lower o

. >> and there was an fda decision in hepatitis c expecting to enter the market where gilead and others treating a lot of patients. how do you view the landscape there. >> we're excited to have an opportunity to come in with competition where there is significant unmet need and looking forward to bringing this product. it is an area where merck has a lot of history. we've been involved in hep c. and we think it could make a huge difference to the health care system and the patients. >> how are you looking at the prices. >> i won't talk about our pricing or go-to market strategy here. but i will say we believe we have a competitive regimen. >> so we shouldn't expect big discounts. >> as i said, i won't talk about the pricing strategy. but we think that we have a competitive regimen that could make a huge difference in the market place. >> let's talk about what you are doing in amino oncology. keytruda is exciting, people are excited about it. you announced today that you are expanding that pipeline. how are you looking at that drug and how does the pricing cost come into that in terms of

gilead, valeant, eli lilly, pfizer all in the green, hopefully you own some of these stocks. take a look at auto stocks right now. it's a mixed bag but i have to tell you u.s. auto sales on track to report a record-breaking 2015, thank you, low gasoline prices across this country. mixed bag, ford gm down a little bit, nissan pushing its way into the green. yes, we are fighting our way back to the closing bell. all three indices back and forth over the unchanged line. what do you make of all of this? let's get to the floor show. experts lined up at the cme group and the nymex and ashley webster on the floor of the new york stock exchange. no conviction, ashley, at all today? >> none at all. this time exactly 24 hours ago, i looked up and the dow was up 410. the dow, the markets been able to fight off lower oil, confusion over the oil patch. the tensions going on in the middle east would naturally have you think the oil should be spiking, but because of that tremendous oversupply, despite what's going on between saudi arabia and iran, the oil market itself is coming down, the d

gilead is going to be a huge one to watch. pfizer that day as well. just tomorrow.nesday next week, thursday aztra zeneca. folks are hoping the earnings growth will drag bio tech out of this but we're really not tading on fundamentals right now. >> it's a good point. cramer of bristol myers says they have an extraordinary cancer franchise. celgene says i think it's cheap and this morning he said don't give up on lily. >> when the whole index though tripled was it trading on fundamentals then? so what we're really talking about is multiple expansion followed by multiple contraption when risk appetites dry up. i agree with you. it's not that all of a sudden all these drug trials are failing. it's that people don't want to pay 80 times earnings. >> more of the more toxic names. >> look at it equal weighted at its worst down 43% from its high. if you pick out four or five of the biggest names in there you weren't trading at the multiples right now. the amgenes of the world weren't trading at that. they have used this as a spot. >> it's a presidential punching bag. >> ab

so i do know that one of the names that len likes in gilead. been long rumored that they have to do a deal for this shock to get out of the funk that it's in. it's very cheap, no doubt, but i don't think people are going to pay for it unless they do -- do you see them doing a deal and what is the perfect fit in your opinion for them? >> sure. and i've said this for a while. i think gilead which is trading at eight times earnings needs to do a transformative deal like they did with pharma set four years ago in order to be able to get the growth rate back. i think that they will have a hard time growing earnings between 2016 and 2019 when their pipeline starts to kick in. the pipeline is very, very good. the perfect company for them to acquire in my opinion is one that would get them more in the oncology space. right now they are a very minor player in the oncology space with only a couple hundred million in revenues, one drug, i think that the ideal can company for them to acquire is a large cap company celgene, where they would become very sign

abigail: gilead sciences, the stock is down today on big news.the current ceo is stepping down effect of march 10 john milligan will be replacing martin. is a real character, he has been a public face for the company for a long time and investors really like him. driving the stock down is the news that merck's drug was recently approved. some competition. gilead is the 800 pound gorilla -c to -- hep-c space. ♪ vonnie: welcome back to "bloomberg ." nissan recalling thousands of bits midsized ultima's for a third time. 846,000 cars made between 2013 and 2015. no crashes or injuries have been reported. one of rupert murdoch's sons bounces back, becoming the chairman of sky tv. he was caught accessing the phones of people the newspaper was covering. apple is working with partners in the u.s. and asia to develop wireless charging technology. it could be launched on its mobile devices as soon as next year. iphones and ipads generate two quarters of apple's revenue. stephanie: the beginning of 2016 brought with it a market monsoon and heightened war

amazon.com absolutely crushed on a disappointing number, netflix, also a couple of health care names, gilead was down but everything else, guys, back to you. david: let's hope we don't go to negative interest rates, but meanwhile we'll take the gain melissa. melissa: joining me now, financial times u.s. managing editor, thanks to both of you for joining us. damon, let me start with you. i am confused by the two indicators here. because if you look at today, what a tremendous rally to end the day to end the week 400 points. but as goes january, so goes the year according to so many metrics. i mean almost 90% of the time. which one do you focus on, david? >> well, i focus on what the conditions are going forward. coming into january, the big concerns was the fed rate hike and the ecb that was less dubbish and wandered. right now we have monetary easing around the world, which i think is going to force the fed to stay lower longer and keep those four rate hikes away. and now with a ten-year treasury at about 1.9 and s&p 500 yield at about 2.3, that's a huge gap for the next foreseeable future.

contacts at gilead have made extraordinary progress. number one driver of our employees is to find better treatments for patients here in the u.s. and worldwide. now, understandably, people are concerned about how to get access and afford some of those treatments, and what we need to do as an industry is work harder to work with other stake holders, including potentially members of government, to make sure that pricing is sustainable. that we get a decent return for the risk that's taken on those drug discoveries. that scientists get rewarded for all the risks and hard work they did. we also get the balance right to make sure that every day people can afford these medicines. we need to do a better job of making sure that conversation is going forward, it's progressive, and we get to a situation where we can continue to be optimistic for great treatments and potentially cures for other diseases we worry about today, like cancer, like alzheimer's, like dementia. these are the diseases we have to make progress on now. >> are you changing y

three of the quick losers as we go out, electronic arts, gilead sciences and netflix. bye. e.s. higher oil prices help. japan trying to stimulate markets. markets love that. they are fair bastions that don't like government interference. the fact they do. they love it more than anyone. any hint that the government will step in to help them out they will happily take. a lot of sectors have turned things around. it is not benefiting amazon. one of the hits de jure, i mean hits as in selling off on very disappointing earnings. record earnings apparently way shy of estimates. those stocks are taking it on the chin. but by and large, a lot of various groups, consumer discretionary, those stocks that tend to do very, very well, oil companies slight uptick minus chevron. i should stress across the board especially when you get to financials and stable rates and talk maybe the federal reserve goes slow on follow-up rate hikes, add it all up we have got good times. i do want to get into that first. also talk about the gap in male and female pay here that the white house is pursuing. fi

amazon, gilead sciences, declining today on a change at the top.tocks that the most to individually damage what is going on at the nasdaq. in terms of today, the nasdaq is rallying. the individual stocks that are contributing the most today to gains, microsoft, out with earnings and rising on those numbers, apple, facebook also, trading on the record, and alphabet finally there. amazon would be the notable outlier of these large-cap tech stocks that are up today. amazon is down today on the innings report coming in below estimates. and then just for fun, the graphic of jeff bezos, his market cap -- in other words from his investment in amazon and what it has done the past several years. down today, but still $48 million. that is not even his total net worth, of course. scarlet: that's a strong. that's ok. thank you so much. let's talk a little bit about amazon going forward, because when you look at the company, as julie mentioned, the shares are getting hammered on when the property failed to deliver better earnings. holiday sales were up 22% but

wells fargo, gilead and comcast the parent of this network, comcast is up 1%.ng cnbc, first in business worldwide. >>> now the latest from trading nation.cnbc.com and a word from our sponsor. >> health insurer centene announcing it is missing six hard drives containing personal data. however it says the drives don't contain financial or payment data. staple replacing its north american stores chief. he will depart stores on the 31st. wlets' go to tyler mathisen at the morning star fund manager of theier awards. >> winner in the alternatives category for 2015678 take a look. >> the 2015 morning star alternatives managered of year go to vanguard market neutral. >> in a year like 2015 where it was val tile it was hard to find positive returns in a lot of asset classes. we were looking to see particularly in markets that were down did they provide good draw down protection and did they provide that concorrelated exposure investors want. the s&p was down 6% in the third quarter. this fun was up 7%. that's mostly where the returns for the year came from. their short

gilead is hitting a all time low as moerk moves higher. john martin is being replaced and remaintains his post of executive chairman. >> the zika virus can cause feverish symptom and birth defects. so far 31 travel associated cases in the u.s. and american airlines saying it's too early to tell what impact this will have on travel. >> in the fight against zika, oxi tech is working on a genetically modified moss keet co-to help combat the spreading virus. joining us now is randal kirk and meg terrell who closely covers the space. >> thank you for joining us. >> thank you, meg. >> i'm very curious to know, given the status of where you are testing this technology and concerns about it, can this make a dent in this zika outbreak we're seeing right now? >> very definitely. we think we have the only proven practical and ready to deploy solution. >> tell us where it's being deployed already and whether it's even being considered to help with olympics ahead of when they start this summer in rea i don't -- rio? >> currently deployed in brazil and

look at some of the movers within the biotech index, really moving on today's news, gilead sciences isn by about 5%, losing the ceo who orchestrated the pharma set purchase which gave it the blockbuster pipeline of the hepc products. and they beat, but the humira sales in the united states, blockbuster arthritis drug, that was disappointing, those sales slowed. that stock is down by 2.5% right now. >>> the metals market is closing for the week. we got to take a check on gold. wild week in the market. gold closing out at 1116.70. stronger dollar dampening some trades here. silver, copper, palladium, platinum in the green. palladium, biggest gains, up by about 1%. >>> to the bond market we go. rick santelli is tracking the action at cme. >> let's look at the five year, shall we? down 6 on the day, down 14 on the week. let's look at a one year chart of fives. we're at 134 basis points. we all know the japanese moved in the negative territory. and in terms of, hey, if you're park the money with bank of japan, you'll have a penalty rate, similar to the situation in europe. let's look at a e

regeneron down 6, gilead down nearly 4. just for context i believe healthcare, consumer discretionary have doubled in value over the last five years. >> maybe a correction is in -- is called for. >> let's talk about general moto motors. the auto maker a half a billion dollar investment in lyft which is only three years old when you think about that. gm will reportedly work with the ride sharing service. a couple things, one, you will be able to develop hubs where drivers can rent gm cars to use as part of their service in lyft and eventually work on an on demand service using autonomous cars, driverless cars. >> how about that. let's get reaction from auto analyst james albertine. good to have you with us. general motors shares were down along with the broader market. any reason investors wouldn't be pleased with this lyft investment. >> it's hard to peele away the reaction to the investment on a day like today. i think most importantly i think what this says is two things, first is it's going to be a cooperative effort bet

gilead had been larger last year in market cap than merck. the largest amount of balance sheet capacity of any of these companies out there given how much cash flow it produces and how little debt it has. >> you want to see interesting things? go back to morgan stanley. a stock that's repealed much of the gains since 2013. that is somewhat devastating people to see that kind of big decline. ruth porat not there anymore. >> the declines in the banks alone whether it's jpmorgan down 14%. morgan stanley down 18%. citi down 17%. goldman down 13% this is 2016 numbers i'm talking about, it's extraordinary. >> fixed income -- trading at citi, not bad. still waiting to see who did not do well in trading. goldman sachs, you talk about goldman sachs book value, you're get nothing situations where they can stand there and buy. if you think there's not going to be rate hikes, you say wait a second, the margin will not go up for jpmorgan. >> they don't ring a bell at the bottom what do i want to look for? >> i think you want to -- at this particular point

cisco, wells fargo, gilead and comcast. power lunch will be right back. >>> and now the latest from trading nation.cnbc.com and a word from our sponsor. >> some people say trading in the after hours session is like trading in the wild wild west. and while there is nothing wrong with trading in the post market, it is important to realize that the spreads are probably going to be wider, the liquidity is probably going to be lower and the risk is definitely going to be higher. if you have medicare parts a and b and want more coverage, guess what? you could apply for a medicare supplement insurance plan whenever you want. no enrollment window. no waiting to apply. that means now may be a great time to shop for an aarp medicare supplement insurance plan, insured by unitedhealthcare insurance company. medicare doesn't cover everything. and like all standardized medicare supplement insurance plans, these help cover some of what medicare doesn't pay. so don't wait. call now to request your free decision guide. it could help you fin